Bristol Myers Squibb won Food and Drug Administration approval for expanded use of its arthritis drug Orencia as the first U.S. drug for the prevention of acute graft-versus-host disease. The story "FDA OKs Bristol Myers' Orencia in Acute Graft-Vs-Host Disease", published on Dec. 15, inaccurately described the final indication.

(END) Dow Jones Newswires

December 20, 2021 09:13 ET (14:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Bristol Myers Squibb.
Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Bristol Myers Squibb.